Open AccessFeatures of modern diagnostics and pharmacotherapy of peripartum cardiomyopathy
Author(s) -
Павел Геннадьевич Мадонов,
AUTHOR_ID,
Л. Д. Хидирова,
V.D. Kazantseva,
AUTHOR_ID,
AUTHOR_ID
Publication year - 2021
Publication title -
journal of siberian medical sciences
Language(s) - English
Resource type - Journals
ISSN - 2542-1174
DOI - 10.31549/2542-1174-2021-4-134-148
Subject(s) - peripartum cardiomyopathy , medicine , pharmacotherapy , bromocriptine , heart failure , pregnancy , cardiomyopathy , cardiology , preeclampsia , intensive care medicine , prolactin , biology , hormone , genetics
The review considers the features of modern diagnostics, pharmacotherapy and prevention of peripartum cardiomyopathy (PPCM). The significance of modern markers of PPCM is discussed: PAI-1, miR-146a, 16 kDa-PRL, sFlt-1/PlGF, interferon-gamma, asymmetric dimethylarginine and the role of diagnostic tests (echocardiography, magnetic resonance imaging), the use of which depends on gestational age and the course of PPCM. The information on indications, complications and clinical experience of the use of the main pharmacological drugs used in the treatment of PPCM, taking into account their possible adverse effects on the fetus and lactation, is given. A new algorithm for the treatment of PPCM, called the BOARD concept (bromocriptine, oral therapy of chronic heart failure (CHF), anticoagulants, vasodilators and diuretics), is being considered, in which the use of bromocriptine and anticoagulants is added to the conventional therapy of CHF, as well as preventive measures for the management of patients with PPCM, taking into account the risk of relapse with persistent left ventricular dysfunction during and after pregnancy.